Skip to content
by Legal Desire
SIGN IN GO PRO
Lawyer profile

Mark Roeder

Latham & Watkins LLP
Claim this profile
Firm
Latham & Watkins LLP
Practice
corporate, Healthcare & Life Sciences, transactional
Office
Bay Area, Silicon Valley
Active in the record
2020 to 2026

Deal experience

Deal types
Banking & FinanceCapital Markets & IPODebt Capital MarketsJoint VentureM&AVenture Capital & Growth
Sectors
Healthcare & Life SciencesTechnology
Jurisdictions
United States

Recent deals

21 announced deals in the record
Latham & Watkins Advises IDEAYA Biosciences on US$300 Million Offering of Common Stock and Pre‑Funded Warrants 11 Jun 2026
Capital Markets & IPO Healthcare & Life Sciences Latham & Watkins LLP USD 300m Lead corporate Bay Area
Latham & Watkins Advises Ascendis Pharma on Nasdaq Ordinary Share Listing 27 Apr 2026
Capital Markets & IPO Healthcare & Life Sciences Latham & Watkins LLP Lead corporate Bay Area
Latham & Watkins Advises 4D Molecular Therapeutics on US$100 Million Offering of Common Stock and Pre-Funded Warrants 8 Nov 2025
Capital Markets & IPO Healthcare & Life Sciences Latham & Watkins LLP USD 100m Lead corporate Bay Area
Latham & Watkins Advises Arcus Biosciences in US$250 Million Public Offering of Common Stock 4 Nov 2025
Capital Markets & IPO Healthcare & Life Sciences Latham & Watkins LLP USD 250m Lead corporate Bay Area
Latham & Watkins Advises Arcus Biosciences in US$150 Million Offering of Common Stock 19 Feb 2025
Capital Markets & IPO Healthcare & Life Sciences Latham & Watkins LLP USD 150m Lead corporate Bay Area
Latham & Watkins Advises Revolution Medicines in Upsized US$750 Million Public Offering of Common Stock and Pre-Funded Warrants 5 Dec 2024
Capital Markets & IPO Healthcare & Life Sciences Latham & Watkins LLP USD 750m Lead corporate Bay Area
Latham & Watkins Advises Ascendis Pharma in US$150 Million Royalty Financing 9 Sept 2024
Debt Capital Markets Healthcare & Life Sciences Latham & Watkins LLP USD 150m Lead transactional
Latham & Watkins Advises Arcus Biosciences in US$250 Million Growth Facility 31 Aug 2024
Banking & Finance Healthcare & Life Sciences Latham & Watkins LLP USD 250m Lead transactional
Latham & Watkins Advises IDEAYA Biosciences in Public Offering 2 Nov 2023
Capital Markets & IPO Healthcare & Life Sciences Latham & Watkins LLP USD 144m Lead corporate Bay Area
Latham & Watkins Advises Ascendis Pharma A/S in Its Royalty Funding Agreement With Royalty Pharma 7 Sept 2023
Debt Capital Markets Healthcare & Life Sciences Latham & Watkins LLP USD 150m Lead
Deal alerts PRO

Get an email when Mark Roeder is named on a newly announced deal.

See Pro plans

Alerts come as one daily email at most.

Pro

See all 21 deals for Mark Roeder

This page shows the 10 most recent. The paid plans open the complete history for this lawyer, with full filtering, plus:

  • Complete deal history, filtered by keyword, deal type, sector and year
  • Deals by year, sector and deal type
  • Frequent co-counsel and the firms most often on the other side
  • Repeat clients, as named in the announcements
  • CSV and Excel export
SEE PLANS SIGN IN
Is this you?

Claim your profile to add your title, a biography and a photo, and show a verified badge. It is free.

Claim this profile

Suggest a correction